Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
Abbott has previously opposed legislation to test strips, but noted an 89% increase in fentanyl deaths in Texas over the past year.
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
How AI will transform mental health support for patients with breast cancer
2.
Genetics and therapy type determine second cancer risk after childhood treatment, study finds
3.
NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.
4.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
5.
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll
1.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
2.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
3.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
4.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
5.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
5.
Navigating the Complexities of Ph Negative ALL - Part XV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge